188 related articles for article (PubMed ID: 30297863)
41. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.
Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M
FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983
[TBL] [Abstract][Full Text] [Related]
42. A suboptimal 5' splice site downstream of HIV-1 splice site A1 is required for unspliced viral mRNA accumulation and efficient virus replication.
Madsen JM; Stoltzfus CM
Retrovirology; 2006 Feb; 3():10. PubMed ID: 16457729
[TBL] [Abstract][Full Text] [Related]
43. A positively selected APOBEC3H haplotype is associated with natural resistance to HIV-1 infection.
Cagliani R; Riva S; Fumagalli M; Biasin M; Caputo SL; Mazzotta F; Piacentini L; Pozzoli U; Bresolin N; Clerici M; Sironi M
Evolution; 2011 Nov; 65(11):3311-22. PubMed ID: 22023594
[TBL] [Abstract][Full Text] [Related]
44. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
45. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region.
Baraz L; Hutoran M; Blumenzweig I; Katzenellenbogen M; Friedler A; Gilon C; Steinitz M; Kotler M
J Gen Virol; 2002 Sep; 83(Pt 9):2225-2230. PubMed ID: 12185277
[TBL] [Abstract][Full Text] [Related]
46. APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction.
Salamango DJ; Becker JT; McCann JL; Cheng AZ; Demir Ö; Amaro RE; Brown WL; Shaban NM; Harris RS
Mol Cell Biol; 2018 Dec; 38(23):. PubMed ID: 30224517
[TBL] [Abstract][Full Text] [Related]
47. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
48. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
[TBL] [Abstract][Full Text] [Related]
49. Structural basis of chimpanzee APOBEC3H dimerization stabilized by double-stranded RNA.
Matsuoka T; Nagae T; Ode H; Awazu H; Kurosawa T; Hamano A; Matsuoka K; Hachiya A; Imahashi M; Yokomaku Y; Watanabe N; Iwatani Y
Nucleic Acids Res; 2018 Nov; 46(19):10368-10379. PubMed ID: 30060196
[TBL] [Abstract][Full Text] [Related]
50. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
51. Computational Investigation of APOBEC3H Substrate Orientation and Selectivity.
Hix MA; Cisneros GA
J Phys Chem B; 2020 May; 124(19):3903-3908. PubMed ID: 32321250
[TBL] [Abstract][Full Text] [Related]
52. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
53. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
Dang Y; Wang X; Esselman WJ; Zheng YH
J Virol; 2006 Nov; 80(21):10522-33. PubMed ID: 16920826
[TBL] [Abstract][Full Text] [Related]
54. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
55. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.
Jaguva Vasudevan AA; Hofmann H; Willbold D; Häussinger D; Koenig BW; Münk C
J Mol Biol; 2017 Apr; 429(8):1171-1191. PubMed ID: 28315663
[TBL] [Abstract][Full Text] [Related]
56. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.
Khan MA; Akari H; Kao S; Aberham C; Davis D; Buckler-White A; Strebel K
J Virol; 2002 Sep; 76(18):9112-23. PubMed ID: 12186895
[TBL] [Abstract][Full Text] [Related]
57. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
58. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
59. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
[TBL] [Abstract][Full Text] [Related]
60. Analysis of single-nucleotide polymorphisms in the APOBEC3H gene of domestic cats (Felis catus) and their association with the susceptibility to feline immunodeficiency virus and feline leukemia virus infections.
de Castro FL; Junqueira DM; de Medeiros RM; da Silva TR; Costenaro JG; Knak MB; de Matos Almeida SE; Campos FS; Roehe PM; Franco AC
Infect Genet Evol; 2014 Oct; 27():389-94. PubMed ID: 25173082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
